NEW YORK (GenomeWeb) –  Biocept reported after the close of the market Thursday that its third quarter 2017 revenues rose around 10 percent year over year.

The liquid biopsy assay developer reported total revenues of $1.1 million for the three months ended Sept. 30, up from $1 million in the same period last year.

Of the $1.1 million of revenues recognized during Q3 2017, $900,000 was revenues recognized on an accrual basis and $102,000 reflected the receipt of cash. Biocept converted from cash-based to accrual-based reporting in Q1 of this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.